Theophylline ER 450 mg study design [Design Issues]

posted by Ramesh Ramalingam  – India, 2018-10-18 07:16 (772 d 23:53 ago) – Posting: # 19463
Views: 1,322

Dear Members,

Based on literature reference, Theophylline is a narrow therapeutic index drug. As per USFDA recommendation if the drugs falls under narrow therapeutic index, the BE study should be a fully replicated crossover design in order to:
• Scale bioequivalence limits to the variability of the reference product; and
• Compare test and reference products within-subject variability.

But respective molecule OGD (which was issued on 2010) Draft guidelines recommending two-way cross-over study design.

Could you please suggest the study design whether it should be two-period, two-way crossover design or four period, fully replicated design.


Regards,
Ramesh

Complete thread:

Activity
 Admin contact
21,216 posts in 4,427 threads, 1,481 registered users;
online 8 (0 registered, 8 guests [including 8 identified bots]).
Forum time: Sunday 06:09 CET (Europe/Vienna)

Half the harm that is done in this world
Is due to people who want to feel important.    T. S. Eliot

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5